August 20, 2020 -- Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with a tender offer to purchase all outstanding shares of Momenta for $52.50 per share.
The acquisition will expand Johnson & Johnson's ability to enter the autoantibody-driven disease market. The deal includes full global rights to nipocalimab (M281), a clinically validated anti- neonatal Fc receptor (FCRN) antibody. The drug has received a rare pediatric disease designation from the U.S. Food and Drug Administration. The company expects nipocalimab to help it achieve above-market growth in the mid and long term.
In addition to Momenta's employees and lead asset, Johnson & Johnson will acquire Momenta's full pipeline of clinical and preclinical assets. Johnson & Johnson plans to retain Momenta's presence in Cambridge, MA. The site will increase Johnson & Johnson's existing innovation footprint and capabilities in the greater Boston area.
The deal is expected to close in the second half of 2020.
Copyright © 2020 scienceboard.net